Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Clinical Oncology

• Publication date

  2007-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.10.5460PMID 17679727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

  2007cited by this paper
• Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

  2006cited by this paper
• Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

  2006cited by this paper
• Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function.

  2006cited by this paper
• International uniform response criteria for multiple myeloma

  2006cited by this paper
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Combination Therapy with Velcade, Doxil, and Dexamethasone (VDD) for Patients with Relapsed/Refractory Multiple Myeloma (MM).

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Evidence That Mitogen-Activated Protein Kinase Phosphatase-1 Induction by Proteasome Inhibitors Plays an Antiapoptotic Role

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• Repression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase-1 by Anthracyclines Contributes to Their Antiapoptotic Activation of p44/42-MAPK

  2003cited by this paper
• The proteasome as a target for cancer therapy.

  2003cited by this paper
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

  2003cited by this paper
• American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

  2002cited by this paper
• Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Multiple myeloma

  2001cited by this paper
• Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

  1998cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A multiple testing procedure for clinical trials.

  1979cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

  2025cites this paper
• Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician’s Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma

  2025influential citation
• Transforming Medicine: Cutting-Edge Applications of Nanoscale Materials in Drug Delivery

  2025cites this paper
• PLGA Polymers and Doxorubicin for the Treatment of Malignant Gliomas in Adults: An Overview

  2025cites this paper
• Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective

  2025cites this paper
• Efficacy and safety of a modified DVD regimen followed by lenalidomide for the treatment of Newly Diagnosed Multiple Myeloma

  2025cites this paper
• Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis

  2025cites this paper
• Developments in nanotechnology approaches for the treatment of solid tumors

  2025cites this paper
• Carfilzomib plus pomalidomide and dexamethasone as salvage therapy in patients with relapsed or refractory multiple myeloma in China: a retrospective study

  2025cites this paper
• Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline

  2025cites this paper
• Exploring cellular immunotherapy platforms in multiple myeloma

  2024influential citation
• Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

  2024cites this paper
• Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma

  2024cites this paper
• A Short Course of Standard Velcade/Dexamethasone Followed by Unlimited Weekly Maintenance Therapy Is an Effective Treatment in Relapsed/Refractory Multiple Myeloma

  2024cites this paper
• Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer

  2024cites this paper
• Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis

  2024cites this paper
• Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies.

  2024cites this paper
• Recent advances in targeted drug delivery systems for multiple myeloma.

  2024cites this paper
• Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy

  2024cites this paper
• An overview of randomized phase III clinical trials of cancer nanomedicines

  2024influential citation
• Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

  2024cites this paper
• Disparities in Multiple Myeloma Mortality Rate Trends by Demographic Status in the USA.

  2024cites this paper
• Commonly prescribed medications associated with alopecia.

  2023cites this paper
• Therapeutic induction of antigen-specific immune tolerance

  2023cites this paper
• Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

  2023cites this paper
• Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review

  2023cites this paper
• Liposomal drug formulations for treatment of hematological malignancies

  2023cites this paper
• Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies

  2023cites this paper
• Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2023cites this paper
• Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

  2023cites this paper
• Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis

  2023cites this paper
• Hydroxyl-Rich Hydrophilic Endocytosis-Promoting Peptide with No Positive Charge

  2022cites this paper
• Multiples Myelom

  2022cites this paper
• Effect modification in network meta-analyses of treatments for relapsing refractory multiple myeloma (RRMM): systematic review, meta-analysis, and simulation

  2022cites this paper
• Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.

  2022cites this paper
• Pathogenesis and treatment of multiple myeloma

  2022cites this paper
• Supportive care in multiple myeloma

  2022cites this paper
• Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice

  2022cites this paper
• A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)

  2022cites this paper
• In vitro and ex vivo anti-myeloma effects of nanocomposite As4S4/ZnS/Fe3O4

  2022cites this paper
• Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

  2022cites this paper
• Oleanolic Acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma.

  2022cites this paper
• Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia

  2022cites this paper
• Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety

  2021cites this paper
• Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy

  2021cites this paper
• Doxorubicin hydrochloride liposome and albumin-bound paclitaxel in cancer: a nanotechnology perspective

  2021cites this paper
• Mechanisms and Potential Treatment Options of Heart Failure in Patients With Multiple Myeloma

  2021influential citation
• Impact of the National Health Insurance Coverage Policy on the Utilisation and Accessibility of Innovative Anti-cancer Medicines in China: An Interrupted Time-Series Study

  2021cites this paper
• Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.

  2021cites this paper
• Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis

  2021cites this paper
• Randomized Controlled Trials versus Single Cohort Studies in Relapse Refractory Multiple Myeloma

  2021influential citation
• Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany

  2021cites this paper
• The evolving role and utility of off-label drug use in multiple myeloma

  2021cites this paper
• Multiple Myeloma: an 11-year of Experience in South Egypt Cancer Institute

  2021cites this paper
• Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

  2021cites this paper
• Multiple Myeloma-Related Peripheral Neuropathy

  2021cites this paper
• Improved efficacy and safety of low-dose oxaliplatin/pegylated liposomal doxorubicin/S-1 regimen in advanced gastric cancer: a cohort study.

  2021cites this paper
• A Retrospective Study of Pegylated Liposomal Doxorubicin Combined with S-1 and Low-dose Oxaliplatin as First-Line Treatment for Advanced Gastric Cancer

  2020cites this paper
• Chemotherapy-based regimens in multiple myeloma in 2020.

  2020cites this paper
• The effect of rat nerve growth factor combined with vitamin B on peripheral neuropathy in multiple myeloma patients

  2020cites this paper
• The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

  2020cites this paper
• Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

  2020cites this paper
• Critical Appraisal of Published Indirect Comparisons and Network Meta-Analyses of Competing Interventions for Multiple Myeloma.

  2020cites this paper
• Population-based meta-analysis of bortezomib exposure–response relationships in multiple myeloma patients

  2020cites this paper
• Evolving role of biomaterials in diagnostic and therapeutic radiation oncology

  2020cites this paper
• What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.

  2020cites this paper
• Protein Engineering and Structural Characterisation Approaches Aimed Towards the Improvement of Biological Therapies

  2020cites this paper
• Winning the Fight Against Cancer.

  2020cites this paper
• Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.

  2019cites this paper
• Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia

  2019cites this paper
• PB2183 SUPERIORITY OF CYBORD OVER VAD IS MORE EVIDENT IN FIRST THAN IN SECOND LINE TREATMENT OF MULTIPLE MYELOMA

  2019cites this paper
• High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment

  2019cites this paper
• 1 High-Risk Multiple Myeloma : Integrated Clinical 2 and Omics Approach Dissects the Neoplastic Clone 3 and the Tumor Microenvironment 4

  2019cites this paper
• Electrospray Functionalization of Titanium Dioxide Nanoparticles with Transferrin for Cerenkov Radiation Induced Cancer Therapy.

  2019cites this paper
• Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy

  2019cites this paper
• Treatment of relapsed and refractory multiple myeloma

  2019cites this paper
• Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy

  2019cites this paper
• Passive Targeting of Nanoparticles to Cancer

  2019cites this paper
• A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

  2019cites this paper
• Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

  2019cites this paper
• Massive pleural effusion due to IgG-Kappa subtype multiple myeloma: A case report☆

  2019cites this paper
• Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials

  2019cites this paper
• Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

  2019cites this paper
• Management of cardiovascular risk in patients with multiple myeloma

  2019cites this paper
• Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

  2019cites this paper
• Adverse Hair Reactions to New Targeted Therapies for Cancer

  2019cites this paper
• Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data.

  2019cites this paper
• BTT_A_166310 33..51

  2019cites this paper
• Multiples Myelom

  2019cites this paper
• Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

  2019cites this paper
• Adverse Hair Reactions to New Targeted Therapies for Cancer.

  2019cites this paper
• Multiple Myeloma

  2019cites this paper
• A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market.

  2019cites this paper
• Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma

  2018cites this paper
• Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis

  2018cites this paper
• Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

  2018cites this paper
• Particles and Nanoparticles in Pharmaceutical Products

  2018cites this paper
• Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study

  2018cites this paper
• The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma

  2018cites this paper
• The start of a new wave: Developments in proteasome inhibition in multiple myeloma

  2018cites this paper